Myant acquires mmHg Inc. to enhance precision medicine for cardiovascular care
Summary
Health care providers can remotely track and analyze blood pressure and a spectrum of vital cardiovascular indicators through its software. The result is early disease detection that improves health outcomes, reduces hospital visits and enhances the quality of life. This acquisition enhances our ability to offer comprehensive cardiovascular monitoring and risk management solutions, strengthening our role in transforming digital health and enabling this large aging demographic to live younger, longer,” says Tony Chahine, CEO at Myant. “The combination of Myant’s cutting-edge textile technology and mmHg’s clinically-infused software architecture will no doubt create the next generation of personalized care-delivery, where patients will be able to transmit clinical-grade, continuous vitals data feeds to a platform that presents the data in an efficient and clinically relevant manner to care teams,” said Peter Wood, co-founder and COO at mmHg Inc. This acquisition aligns with Myant’s ongoing efforts to leverage AI and advanced materials to improve patient outcomes and extend human life.